

Press release 2022-09-20



ArgusEye closes deal with the downstream group within biological development at Bayer AG.

The multinational pharmaceutical and biotechnology company, Bayer AG, has decided to purchase an in-line sensor system from ArgusEye AB (Linköping, Sweden) to accelerate their development of new therapies based on biopharmaceuticals.

The sensor system, ArgusOne, developed and provided by ArgusEye enables faster and more precise monitoring of biopharmaceuticals during process development and production. ArgusOne provides valuable real-time data directly during purification and replaces time-consuming lab-based analyses.

"We at Bayer are constantly looking for new, disruptive technologies that can make our production and process development faster and more intensified," said Bastian Budde, lab head downstream process development at Bayer. "The technology from ArgusEye has unique capabilities for in-line detection and analysis, and it will be a great asset for our downstream process development team"

"We are very happy that Bayer has chosen to invest in a sensor system from ArgusEye," said Erik Martinsson, CEO at ArgusEye. "This is yet another confirmation that our sensor systems generate great value for the biopharma industry and can contribute to a faster drug development."

Contact Details:

Erik Martinsson, CEO ArgusEye AB
Telephone: +46 702792477
E-mail: erik.martinsson@arguseye.se

About Us:

ArgusEye provides innovative sensor solutions for real-time monitoring of biological systems and processes. The company's patented sensor technology is the result of extensive academic research and is based on nanoplasmonic sensing combined with fiber optics. Comprising a unique sensor chip technology and flexible flow cells, the sensor systems can be used for a range of target analytes and applications.